Unsettling drug patent settlements: a framework for presumptive illegality

Area of Science:

• Pharmaceutical Law
• Antitrust Law
• Health Economics

Background:

• High drug prices in the U.S. are partly driven by patent litigation settlements between brand-name and generic drug manufacturers.
• The Hatch-Waxman Act (1984) aimed to foster generic competition but has been exploited through reverse-payment agreements.
• Courts have upheld these settlements, citing cost reduction and innovation, despite scholarly and FTC objections.

Purpose of the Study:

• To analyze reverse-payment settlements within the framework of the Hatch-Waxman Act and antitrust law.
• To re-evaluate judicial leniency towards these agreements using the Supreme Court's antitrust analysis framework.
• To propose a revised legal standard for assessing the legality of drug patent settlements.

Main Methods:

• Application of the Verizon Communications v. Law Offices of Curtis V. Trinko, LLP framework to drug patent settlements.
• Analysis of the Hatch-Waxman Act's original intent regarding competition and innovation.
• Examination of the anticompetitive potential and incentives within reverse-payment agreements.

Main Results:

• The Hatch-Waxman Act's mechanisms intended to promote patent challenges have been subverted.
• Reverse-payment settlements, where brand firms pay generics to delay entry, carry significant anticompetitive potential.
• Current judicial leniency overlooks the intended pro-competitive goals of the Act.

Conclusions:

• Antitrust law should presume reverse-payment settlements illegal due to their anticompetitive nature.
• The burden should be on parties to prove payments are a reasonable estimate of litigation success to rebut this presumption.
• Courts should enforce antitrust laws to restore the pro-competitive intent of the Hatch-Waxman Act.